High materiality9/10
Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
Why it may matterVerify against the original reporting
upside potential
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
TVardi Therapeutics upgraded to Outperform by UBS with a $10 target vs a $3.1 price, indicating substantial upside.
- Target well above price; upside ~223%.
Key facts
- 01
Target: $10
- 02
Posted price: $3.1
- 03
Analyst firm: UBS
- 04
Analyst: Ryan Deschner
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.